C4 Therapeutics, Inc.CCCCNASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank57
3Y CAGR-6.2%
5Y CAGR+54.2%
Studio
Year-over-Year Change

Expenses from normal business operations (SG&A, R&D, etc.)

3Y CAGR
-6.2%/yr
vs +45.6%/yr prior
5Y CAGR
+54.2%/yr
Recent deceleration
Acceleration
-51.8pp
Decelerating
Percentile
P57
Within normal range
vs 5Y Ago
8.7x
Strong expansion
Streak
1 yr
Consecutive declineContracting
PeriodValueYoY Change
2025$132.46M-14.7%
2024$155.20M+2.1%
2023$152.05M-5.3%
2022$160.63M+25.6%
2021$127.92M+741.4%
2020$15.20M-73.2%
2019$56.83M+59.0%
2018$35.75M-